Fewer relapses in MS with off-label drug
Patients with multiple sclerosis (MS) treated with the drug rituximab had a significantly lower risk of relapse compared with MS patients receiving standard treatment. This has been shown in a phase 3 clinical trial by researchers at Karolinska Institutet and Danderyd Hospital in Sweden published in The Lancet Neurology. Rituximab is not approved as an MS drug, but has proven to be effective in smaller studies and is therefore largely prescribed “off label”.The Phase 3 clinical trial is a multicentre study involving 195 patients from 17 hospitals in Sweden newly diagnosed with the most